Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

XenoPort, Inc. announced positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil, also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury. Doses of 20 and 30 mg of AP, given twice daily, demonstrated statistically significant improvements compared to placebo for the primary endpoint of the study.


Today in Other Drugs...keeping you current

Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09

Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09

Biphasic effects of hormone treatment on risk of cardiovascular disease
Sexuality, Reproduction & Menopause, 10/20/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address